Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantActivity from announced rounds
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
Structured data and AI agents for clinical development and pharmaceutical trial operations.
Crossbow Therapeutics develops antibody therapies for cancer.
Develops bispecific antibodies for targeted degradation of extracellular proteins.